[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-426072-105":59,"doc-detail-426072-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","subcutaneous-methylnaltrexone-for-opioid-induced-constipation-in-older-adults-with-advanced-illness","SUBCUTANEOUS METHYLNALTREXONE FOR OPIOID-INDUCED CONSTIPATION IN OLDER ADULTS WITH ADVANCED ILLNESS","","Opioid-induced constipation (OIC) affects up to 81% of patients receiving opioid analgesics and is linked to peripheral mu-opioid receptor binding in the gastrointestinal tract. A posthoc pooled analysis assessed the efficacy and safety of subcutaneous methylnaltrexone in older adults (≥65) with advanced illness. Two randomized, double-blind, placebo-controlled phase 3 trials compared 0.15 or 0.30 mg/kg versus placebo, evaluating rescue medication-free bowel movements within 4 hours. Significantly more patients achieved rapid response with methylnaltrexone across age strata, and the treatment was well tolerated, with conclusions supporting rapid onset and efficacy.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/subcutaneous-methylnaltrexone-for-opioid-induced-constipation-in-older-adults-with-advanced-illness/426072/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/subcutaneous-methylnaltrexone-for-opioid-induced-constipation-in-older-adults-with-advanced-illness/426072.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-06","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What causes opioid-induced constipation (OIC) in this analysis?","Question",{"text":112,"@type":113},"OIC is caused by opioids binding to peripheral mu-opioid receptors in the gastrointestinal tract, leading to constipation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What treatment and dosing were evaluated?",{"text":117,"@type":113},"Patients received subcutaneous methylnaltrexone 0.15 mg/kg or 0.30 mg/kg, or placebo, in two randomized, double-blind, placebo-controlled phase 3 trials.",{"name":119,"@type":110,"acceptedAnswer":120},"How was efficacy measured?",{"text":121,"@type":113},"Efficacy was measured as the percentage of patients achieving a rescue medication-free bowel movement (RFBM) within 4 hours after the first dose.",{"name":123,"@type":110,"acceptedAnswer":124},"Was methylnaltrexone effective and tolerable in older adults with advanced illness?",{"text":125,"@type":113},"Yes. More patients across several age subgroups achieved RFBM within 4 hours with methylnaltrexone than with placebo, and subcutaneous methylnaltrexone was well tolerated.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},426072,1791076722,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":24},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","Innovation in Aging, 2025, Vol. 9, No. S2 1001  \nAbstract citation ID: igaf122.3377  \nSUBCUTANEOUS METHYLNALTREXONE FOR OPIOID-INDUCED CONSTIPATION IN OLDER ADULTS WITH ADVANCED ILLNESS  \nJulie Knight1, Sri Nalamachu2, and Adam Laitman1, 1. Salix Pharmaceuticals, Bridgewater, New Jersey, United States, 2. Analgesic Clinical Research, Blue Springs, Missouri, United States  \nOpioid-induced constipation (OIC), affecting up to 81% of patients taking opioid analgesics, is caused by opioids binding to peripheral mu-opioid receptors in the gastrointestinal tract. Methylnaltrexone, a peripherally-acting mu-opioid receptor antagonist, reverses opioid-related constipating effects without affecting centrally-mediated analgesia. This analysis evaluated subcutaneous methylnaltrexone efficacy/safety in older adults (≥65 years) with advanced illness (eg, incurable cancer) and OIC. In 2 randomized, double-blind, placebo-controlled, phase 3 trials, patients received subcutaneous methylnaltrexone 0.15 or 0.30 mg/kg, or placebo. Primary endpoint (both trials) was percentage of patients with rescue medication-free bowel movement (RFBM) within 4 hours after first dose. Data were pooled and analyzed posthoc. Overall, 161 patients (49.1% female) were included. Significantly more patients aged ≥65 years treated with subcutaneous methylnaltrexone 0.15 (37/68 [54.4%]) or 0.30 mg/kg (16/31 [51.6%]) had an RFBM within 4 hours versus placebo (9/62 [14.5%]; both P \u003C 0.001 vs placebo). When further stratified by age, an RFBM within 4 hours was reported in significantly more patients 65-74 years treated with methylnaltrexone 0.15 (13/31 [41.9%]) or 0.30 mg/kg (8/15 [53.3%]) versus placebo (3/23 [13.0%]; P ≤0.03 for both); for 75-84 years, methylnaltrexone 0.15 (17/25 [68.0%]) or 0.30 mg/kg (7/12 [58.3%]) versus placebo (3/21 [14.3%]; P \u003C 0.001 and P = 0.02 versus placebo, respectively) . For patients aged ≥85 years, significantly more patients had a RFBM within 4 hours in methylnaltrexone 0.15 mg/kg (7/12 [58.3%]) versus placebo (3/18 [16.7%]; P = 0.04) group. Subcutaneous methylnaltrexone was well  \n1002 Innovation in Aging, 2025, Vol. 9, No. S2  \ntolerated. In conclusion, subcutaneous methylnaltrexone for OIC was efficacious, with a rapid onset of action, and well tolerated in older individuals.","cbCaiixmMAFsaL6C","https://ap.wps.com/l/cbCaiixmMAFsaL6C","pdf",52202,"English","# Abstract\n## Background and mechanism\n## Study design and endpoints\n## Results by age subgroup\n## Safety and conclusion","[{\"question\":\"What causes opioid-induced constipation (OIC) in this analysis?\",\"answer\":\"OIC is caused by opioids binding to peripheral mu-opioid receptors in the gastrointestinal tract, leading to constipation.\"},{\"question\":\"What treatment and dosing were evaluated?\",\"answer\":\"Patients received subcutaneous methylnaltrexone 0.15 mg/kg or 0.30 mg/kg, or placebo, in two randomized, double-blind, placebo-controlled phase 3 trials.\"},{\"question\":\"How was efficacy measured?\",\"answer\":\"Efficacy was measured as the percentage of patients achieving a rescue medication-free bowel movement (RFBM) within 4 hours after the first dose.\"},{\"question\":\"Was methylnaltrexone effective and tolerable in older adults with advanced illness?\",\"answer\":\"Yes. More patients across several age subgroups achieved RFBM within 4 hours with methylnaltrexone than with placebo, and subcutaneous methylnaltrexone was well tolerated.\"}]","SUBCUTANEOUS METHYLNALTREXONE FOR OPIOID-INDUCED CONSTIPATION IN OLDER ADULTS WITH ADVANCED ILLNESS | PDF",1790639288]